BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND CDK12, KIAA0904, CRKRS, 51755, ENSG00000167258, CRK7, CRKR, Q9NYV4 AND Prognosis
13 results:

  • 1. Somatic and Germline Variants Affect prognosis and Susceptibility in prostate cancer.
    Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
    Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The prognostic nomogram for PSA-incongruent low-risk prostate cancer treated by radical prostatectomy.
    Wang Y; Zhu Y; Fan L; Liu J; Pan J; Xue W
    Int Urol Nephrol; 2023 Jun; 55(6):1447-1452. PubMed ID: 37017821
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Prognostic and clinicopathological value of cdk12 mutation in prostate cancer: a meta-analysis.
    Zhang W; Zhou L; Di J
    Expert Rev Anticancer Ther; 2023 Feb; 23(2):207-216. PubMed ID: 36734254
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.
    Uemura H; Oya M; Kamoto T; Sugimoto M; Shinozaki K; Morita K; Koto R; Takahashi M; Nii M; Shin E; Nonomura N
    Cancer Med; 2023 Mar; 12(5):5265-5274. PubMed ID: 36358026
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer.
    Zeng Z; He W; Jiang Y; Jiang H; Cheng X; Deng W; Zhou X; Zhang C; Wang G
    BMC Cancer; 2022 Nov; 22(1):1162. PubMed ID: 36357836
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive prostate cancer: A Systematic Review.
    Van der Eecken K; Vanwelkenhuyzen J; Deek MP; Tran PT; Warner E; Wyatt AW; Kwan EM; Verbeke S; Van Dorpe J; Fonteyne V; Lumen N; De Laere B; Ost P
    Eur Urol Oncol; 2021 Dec; 4(6):914-923. PubMed ID: 34801437
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
    Jayaram A; Wingate A; Wetterskog D; Wheeler G; Sternberg CN; Jones R; Berruti A; Lefresne F; Lahaye M; Thomas S; Gormley M; Meacham F; Garg K; Lim LP; Merseburger AS; Tombal B; Ricci D; Attard G
    Ann Oncol; 2021 Jun; 32(6):726-735. PubMed ID: 33794293
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
    Dono A; Takayasu T; Yan Y; Bundrant BE; Arevalo O; Lopez-Garcia CA; Esquenazi Y; Ballester LY
    Neurosurgery; 2021 Feb; 88(3):592-602. PubMed ID: 33369669
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. cdk12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression.
    Yanai Y; Kosaka T; Nakamura K; Aimono E; Matsumoto K; Morita S; Mikami S; Nishihara H; Oya M
    Cancer Sci; 2020 Dec; 111(12):4652-4655. PubMed ID: 33038052
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Characterizing cdk12-Mutated prostate cancers.
    Rescigno P; Gurel B; Pereira R; Crespo M; Rekowski J; Rediti M; Barrero M; Mateo J; Bianchini D; Messina C; Fenor de la Maza MD; Chandran K; Carmichael J; Guo C; Paschalis A; Sharp A; Seed G; Figueiredo I; Lambros M; Miranda S; Ferreira A; Bertan C; Riisnaes R; Porta N; Yuan W; Carreira S; de Bono JS
    Clin Cancer Res; 2021 Jan; 27(2):566-574. PubMed ID: 32988971
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor prognosis in Metastatic Castration-Resistant prostate cancer.
    Guan X; Sun D; Lu E; Urrutia JA; Reiter RE; Rettig M; Evans CP; Lara P; Gleave M; Beer TM; Thomas GV; Huang J; Aggarwal RR; Quigley DA; Foye A; Chen WS; Youngren J; Weinstein AS; Stuart JM; Feng FY; Small EJ; Xia Z; Alumkal JJ
    Clin Cancer Res; 2020 Sep; 26(17):4616-4624. PubMed ID: 32727885
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive prostate cancer.
    Stopsack KH; Nandakumar S; Wibmer AG; Haywood S; Weg ES; Barnett ES; Kim CJ; Carbone EA; Vasselman SE; Nguyen B; Hullings MA; Scher HI; Morris MJ; Solit DB; Schultz N; Kantoff PW; Abida W
    Clin Cancer Res; 2020 Jul; 26(13):3230-3238. PubMed ID: 32220891
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Genomics of lethal prostate cancer at diagnosis and castration resistance.
    Mateo J; Seed G; Bertan C; Rescigno P; Dolling D; Figueiredo I; Miranda S; Nava Rodrigues D; Gurel B; Clarke M; Atkin M; Chandler R; Messina C; Sumanasuriya S; Bianchini D; Barrero M; Petermolo A; Zafeiriou Z; Fontes M; Perez-Lopez R; Tunariu N; Fulton B; Jones R; McGovern U; Ralph C; Varughese M; Parikh O; Jain S; Elliott T; Sandhu S; Porta N; Hall E; Yuan W; Carreira S; de Bono JS
    J Clin Invest; 2020 Apr; 130(4):1743-1751. PubMed ID: 31874108
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.